Litcius/Paper detail

Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial

Deepali Kumar, Michael G. Ison, Jean‐Paul Mira, Tobias Welte, Jick Hwan Ha, David S.C. Hui, Nanshan Zhong, Takefumi Saito, Laurie Katugampola, Neil Collinson, Sarah Williams, Steffen Wildum, Andrew M. Ackrill, Barry Clinch, Nelson Lee

2022The Lancet Infectious Diseases107 citationsDOI

Topics & Concepts

Neuraminidase inhibitorMedicinePlaceboDouble blindRandomized controlled trialNeuraminidasePlacebo-controlled studyInternal medicineAnesthesiaVirologyCoronavirus disease 2019 (COVID-19)PathologyVirusAlternative medicineDiseaseInfectious disease (medical specialty)Influenza Virus Research StudiesRespiratory viral infections researchInfectious Encephalopathies and Encephalitis
Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial | Litcius